Eric Siemers
@ers_net
Followers
357
Following
3K
Media
13
Statuses
919
Neuroscience researcher trying to stop neurodegeneration before it starts. Opinions are my own.
Zionsville, IN
Joined November 2013
For the third year we are honored to support the @alzassociation 's "Walk to End Alzheimer’s" campaign. If you’d like to learn more about how you can support the Acumen team, click the link below: https://t.co/o1YH1crAtv
#EndAlz #TeamAcumen #WalkToEndAlzheimers
0
2
2
Plasma p-tau217 is changing diagnostic testing for Alzheimer’s. Primary care doctors are using it. A startup can speed up clinical workups with in-home testing. Many clinicians are not yet on board. @Memorial_Owosso @ucl @ClevelandClinic @lunduniversity
0
1
9
Our 2025 Alzheimer’s Disease Facts and Figures is a call to action – to do more, to make more progress, and to give people more reasons to believe that our vision of a world without Alzheimer’s and all other dementia is possible.
These numbers tell the story of #AlzheimersInAmerica. Our families, our economy and our communities are straining under the weight of this disease. But together, we can make a difference. Watch 👁️, share ➡️ and join the fight to end Alzheimer’s 💜. #ENDALZ
1
9
23
Important article for the field available in open access: Donanemab: Appropriate use recommendations. G.D. Rabinovici et al. https://t.co/i1ud9diRtj…
#Donanemab @jpreventionalz1
0
3
3
Federal Register Blackout Blocks NIH Funding | MedPage Today
medpagetoday.com
New strategy is like pouring 'cement in the pipes of the federal funding infrastructure'
0
0
1
On behalf of all of my co-authors, I am sharing a collective response to the book "Doctored" by Charles Piller and in response to his NYT article promoting the book. @ApostolovaLiana @grinberg_t @holtzman4 @lab_lamb @clemere99 @MaluTansey @ers_net et al. Full author list shown.
6
29
75
FDA Approves New IV Maintenance Dosing for Alzheimer Treatment Lecanemab
neurologylive.com
Once-monthly maintenance dosing with LEQEMBI offers convenience for patients and caregivers while slowing Alzheimer disease progression and prolonging therapy benefits after plaque clearance.
0
0
1
A Country Doctor, But Oh So Much More: Francisco Lopera, 73 | ALZFORUM
0
0
1
Today’s @Telegraph first to report MHRA approval of #Leqembi - the first drug to show slowing decline of #Alzheimers. Not a wonder drug but the beginning of us having treatments that change the course of disease.
5
16
54
Researchers have announced the release of a massive dataset from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's (A4) and LEARN study – the first and largest clinical trial of pre-symptomatic Alzheimer's disease. https://t.co/TCgIcc9J2k
atrinews.usc.edu
In a win for Alzheimer's research, the largest ever pre-symptomatic disease data is freely available, fueling hope for new treatments.
4
38
100
The #CTAD24 preliminary program is now online! Check out our Oral Communications on Tuesday, October 29! 👇 https://t.co/2cTbSkHR4H
0
3
4
FDA approves treatment for adults with Alzheimer’s disease | FDA
fda.gov
The Food and Drug Administration has approved Kisunla (donanemab-azbt) injection for the treatment of Alzheimer’s disease.
0
0
3
Blood Proteins May Foretell Parkinson’s Disease Up to Seven Years Prior | ALZFORUM
0
0
0
APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer’s Disease @ytquiroz; I vividly remember you presenting this at our @AtypicalPIA symposium at AAIC. Great to see it published @NEJM, congrats!!! Background: In a person with autosomal dominant Alzheimer’s disease
0
7
45
Today we launched our new BioFINDER website! It describes our six ongoing BioFINDER studies in detail. https://t.co/VvDweXfHYW
biofinder.se
BioFINDER was initiated to discover key pathological mechanisms in Alzheimer's disease and other neurodegenerative diseases such as parkinsonian disorders. The generated knowledge will be used to...
We're thrilled to introduce our brand-new website: https://t.co/G5aPBUPApS! 🎉 Explore our cohorts, latest publications, news updates, team profiles, and so much more. Take a look!
2
9
42
At Acumen, we believe in putting people first, and what better way to do that than by shining a spotlight on our incredible team members and the amazing work they do! 🔗Click the link below to read the interview: https://t.co/b2wzBG9nNb
#AskAcumen #EmployeeSpotlight
0
1
2
Interesting progress in the diagnosis of PD and other synucleinopathies.
0
0
2